1
|
Ye P, Duan W, Leng YQ, Wang YK, Tan X, Wang WZ. DPP3: From biomarker to therapeutic target of cardiovascular diseases. Front Cardiovasc Med 2022; 9:974035. [PMID: 36312232 PMCID: PMC9605584 DOI: 10.3389/fcvm.2022.974035] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 09/26/2022] [Indexed: 11/13/2022] Open
Abstract
Cardiovascular disease is the leading cause of death globally among non-communicable diseases, which imposes a serious socioeconomic burden on patients and the healthcare system. Therefore, finding new strategies for preventing and treating cardiovascular diseases is of great significance in reducing the number of deaths and disabilities worldwide. Dipeptidyl peptidase 3 (DPP3) is the first zinc-dependent peptidase found among DPPs, mainly distributes within the cytoplasm. With the unique HEXXGH catalytic sequence, it is associated with the degradation of oligopeptides with 4 to 10 amino acids residues. Accumulating evidences have demonstrated that DPP3 plays a significant role in almost all cellular activities and pathophysiological mechanisms. Regarding the role of DPP3 in cardiovascular diseases, it is currently mainly used as a biomarker for poor prognosis in patients with cardiovascular diseases, suggesting that the level of DPP3 concentration in plasma is closely linked to the mortality of diseases such as cardiogenic shock and heart failure. Interestingly, it has been reported recently that DPP3 regulates blood pressure by interacting with the renin-angiotensin system. In addition, DPP3 also participates in the processes of pain signaling, inflammation, and oxidative stress. But the exact mechanism by which DPP3 affects cardiovascular function is not clear. Hence, this review summarizes the recent advances in the structure and catalytic activity of DPP3 and its extensive biological functions, especially its role as a therapeutic target in cardiovascular diseases. It will provide a theoretical basis for exploring the potential value of DPP3 as a therapeutic target for cardiovascular diseases.
Collapse
Affiliation(s)
- Peng Ye
- Department of Marine Biomedicine and Polar Medicine, Naval Medical Center, Naval Medical University (Second Military Medical University), Shanghai, China
| | - Wei Duan
- Department of Marine Biomedicine and Polar Medicine, Naval Medical Center, Naval Medical University (Second Military Medical University), Shanghai, China,Key Laboratory of Medical Electrophysiology of Ministry of Education, Medical Electrophysiology Key Lab of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China
| | - Yue-Qi Leng
- Department of Marine Biomedicine and Polar Medicine, Naval Medical Center, Naval Medical University (Second Military Medical University), Shanghai, China
| | - Yang-Kai Wang
- Department of Marine Biomedicine and Polar Medicine, Naval Medical Center, Naval Medical University (Second Military Medical University), Shanghai, China
| | - Xing Tan
- Department of Marine Biomedicine and Polar Medicine, Naval Medical Center, Naval Medical University (Second Military Medical University), Shanghai, China,Xing Tan
| | - Wei-Zhong Wang
- Department of Marine Biomedicine and Polar Medicine, Naval Medical Center, Naval Medical University (Second Military Medical University), Shanghai, China,*Correspondence: Wei-Zhong Wang
| |
Collapse
|
3
|
Pang X, Shimizu A, Kurita S, Zankov DP, Takeuchi K, Yasuda-Yamahara M, Kume S, Ishida T, Ogita H. Novel Therapeutic Role for Dipeptidyl Peptidase III in the Treatment of Hypertension. Hypertension 2016; 68:630-41. [PMID: 27456521 DOI: 10.1161/hypertensionaha.116.07357] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 05/26/2016] [Indexed: 01/10/2023]
Abstract
Dipeptidyl peptidase III (DPP III) cleaves dipeptide residues from the N terminus of polypeptides ranging from 3 to 10 amino acids in length and is implicated in pathophysiological processes through the breakdown of certain oligopeptides or their fragments. In this study, we newly identified the biochemical properties of DPP III for angiotensin II (Ang II), which consists of 8 amino acids. DPP III quickly and effectively digested Ang II with Km = 3.7×10(-6) mol/L. In the in vivo experiments, DPP III remarkably reduced blood pressure in Ang II-infused hypertensive mice without alteration of heart rate. DPP III did not affect hemodynamics in noradrenalin-induced hypertensive mice or normotensive mice, suggesting specificity for Ang II. When DPP III was intravenously injected every other day for 4 weeks after Ang II osmotic minipump implantation in mice, Ang II-induced cardiac fibrosis and hypertrophy were significantly attenuated. This DPP III effect was at least similar to that caused by an angiotensin receptor blocker candesartan. Furthermore, administration of DPP III dramatically reduced the increase in urine albumin excretion and kidney injury and inflammation markers caused by Ang II infusion. Both DPP III and candesartan administration showed slight additive inhibition in the albumin excretion. These results reveal a novel potential use of DPP III in the treatment of hypertension and its protective effects on hypertension-sensitive organs, such as the heart and kidneys.
Collapse
Affiliation(s)
- Xiaoling Pang
- From the Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (X.P., A.S., S.Kurita, D.P.Z., K.T., H.O.), Division of Diabetology, Endocrinology, Nephrology, and Neurology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan (M.Y-Y., S.Kume); Chemistry Division, Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus, Nishihara-cho, Japan (T.I.); and Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, China (X.P.)
| | - Akio Shimizu
- From the Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (X.P., A.S., S.Kurita, D.P.Z., K.T., H.O.), Division of Diabetology, Endocrinology, Nephrology, and Neurology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan (M.Y-Y., S.Kume); Chemistry Division, Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus, Nishihara-cho, Japan (T.I.); and Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, China (X.P.)
| | - Souichi Kurita
- From the Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (X.P., A.S., S.Kurita, D.P.Z., K.T., H.O.), Division of Diabetology, Endocrinology, Nephrology, and Neurology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan (M.Y-Y., S.Kume); Chemistry Division, Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus, Nishihara-cho, Japan (T.I.); and Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, China (X.P.)
| | - Dimitar P Zankov
- From the Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (X.P., A.S., S.Kurita, D.P.Z., K.T., H.O.), Division of Diabetology, Endocrinology, Nephrology, and Neurology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan (M.Y-Y., S.Kume); Chemistry Division, Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus, Nishihara-cho, Japan (T.I.); and Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, China (X.P.)
| | - Keisuke Takeuchi
- From the Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (X.P., A.S., S.Kurita, D.P.Z., K.T., H.O.), Division of Diabetology, Endocrinology, Nephrology, and Neurology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan (M.Y-Y., S.Kume); Chemistry Division, Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus, Nishihara-cho, Japan (T.I.); and Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, China (X.P.)
| | - Mako Yasuda-Yamahara
- From the Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (X.P., A.S., S.Kurita, D.P.Z., K.T., H.O.), Division of Diabetology, Endocrinology, Nephrology, and Neurology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan (M.Y-Y., S.Kume); Chemistry Division, Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus, Nishihara-cho, Japan (T.I.); and Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, China (X.P.)
| | - Shinji Kume
- From the Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (X.P., A.S., S.Kurita, D.P.Z., K.T., H.O.), Division of Diabetology, Endocrinology, Nephrology, and Neurology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan (M.Y-Y., S.Kume); Chemistry Division, Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus, Nishihara-cho, Japan (T.I.); and Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, China (X.P.)
| | - Tetsuo Ishida
- From the Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (X.P., A.S., S.Kurita, D.P.Z., K.T., H.O.), Division of Diabetology, Endocrinology, Nephrology, and Neurology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan (M.Y-Y., S.Kume); Chemistry Division, Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus, Nishihara-cho, Japan (T.I.); and Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, China (X.P.)
| | - Hisakazu Ogita
- From the Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (X.P., A.S., S.Kurita, D.P.Z., K.T., H.O.), Division of Diabetology, Endocrinology, Nephrology, and Neurology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan (M.Y-Y., S.Kume); Chemistry Division, Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus, Nishihara-cho, Japan (T.I.); and Department of Emergency, The Fourth Affiliated Hospital of China Medical University, Shenyang, China (X.P.).
| |
Collapse
|
5
|
Borghi C, Omboni S, Reggiardo G, Bacchelli S, Degli Esposti D, Ambrosioni E. Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart 2015; 2:e000220. [PMID: 26380097 PMCID: PMC4567784 DOI: 10.1136/openhrt-2014-000220] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Revised: 06/23/2015] [Accepted: 07/08/2015] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Early administration of zofenopril following acute myocardial infarction (AMI) proved to be prognostically beneficial in the four individual randomised, double-blind, parallel-group, prospective SMILE (Survival of Myocardial Infarction Long-term Evaluation) studies. In the present analysis, we evaluated the cumulative efficacy of zofenopril by pooling individual data from the four SMILE studies. METHODS 3630 patients with AMI were enrolled and treated for 6-48 weeks with zofenopril 30-60 mg/day (n=1808), placebo (n=951), lisinopril 5-10 mg/day (n=520) or ramipril 10 mg/day (n=351). The primary study end point of this pooled analysis was set to 1 year combined occurrence of death or hospitalisation for cardiovascular (CV) causes. RESULTS Occurrence of major CV outcomes was significantly reduced with zofenopril versus placebo (-40%; HR=0.60, 95% CI 0.49 to 0.74; p=0.0001) and versus the other ACE inhibitors (-23%; HR=0.77, 0.63 to 0.95; p=0.015). The risk reduction observed under treatment with the other ACE inhibitors was nearly statistically significant (-22%; HR=0.78, 0.60 to 1.02; p=0.072). The benefit of zofenopril versus placebo was already evident after the first 6 weeks of treatment (-28%; HR=0.72, 0.54 to 0.97; p=0.029), while this was not the case for the other ACE inhibitors (-19%; HR=0.81, 0.57 to 1.17; p=0.262). In this early phase of treatment, zofenopril showed a non-significant trend towards a larger reduction in CV events versus the other ACE inhibitors (-11%; HR=0.89, 0.69 to 1.15; p=0.372). CONCLUSIONS The pooled data analysis from the SMILE Programme confirms the favourable effects of zofenopril treatment in patients with post-AMI and its long-term benefit in terms of prevention of CV morbidity and mortality.
Collapse
Affiliation(s)
- Claudio Borghi
- Unit of Internal Medicine , Policlinico S Orsola, University of Bologna , Bologna , Italy
| | - Stefano Omboni
- Clinical Research Unit , Italian Institute of Telemedicine , Solbiate Arno, Varese , Italy
| | | | - Stefano Bacchelli
- Unit of Internal Medicine , Policlinico S Orsola, University of Bologna , Bologna , Italy
| | - Daniela Degli Esposti
- Unit of Internal Medicine , Policlinico S Orsola, University of Bologna , Bologna , Italy
| | - Ettore Ambrosioni
- Unit of Internal Medicine , Policlinico S Orsola, University of Bologna , Bologna , Italy
| |
Collapse
|